Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

December 7, 2022

https://www.globenewswire.com/news-release/2022/12/07/2569335/0/en/Palisade-Bio-Announces-Early-Exercise-of-Warrants-Resulting-in-Cash-Proceeds-of-1-25-Million.html

Proceeds extend cash runway to fund operations into early 2024

Carlsbad, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that holders of 445,000 common stock purchase warrants (the “Warrants”), issued pursuant to the Company’s August 2022 public offering, have exercised such Warrants for cash. As a result of the exercises, the Company has received gross cash proceeds of approximately $1.25 million.

Read more at globenewswire.com

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.